Elbadry Mahmoud I, Espinoza J Luis, Nakao Shinji
Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; Department of Internal Medicine, Division of Hematology, Faculty of Medicine, Sohag University, Egypt.
Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Exp Hematol. 2019 Mar;71:32-42. doi: 10.1016/j.exphem.2019.01.006. Epub 2019 Jan 19.
The plasticity of induced pluripotent stem cells (iPSCs) with the potential to differentiate into virtually any type of cells and the feasibility of generating hematopoietic stem progenitor cells (HSPCs) from patient-derived iPSCs (iPSC-HSPCs) has many potential applications in hematology. For example, iPSC-HSPCs are being used for leukemogenesis studies and their application in various cell replacement therapies is being evaluated. The use of iPSC-HSPCs can now provide an invaluable resource for the study of diseases associated with the destruction of HSPCs, such as bone marrow failure syndromes (BMFSs). Recent studies have shown that generating iPSC-HSPCs from patients with acquired aplastic anemia and other BMFSs is not only feasible, but is also a powerful tool for understanding the pathogenesis of these disorders. In this article, we highlight recent advances in the application of iPSCs for disease modeling of BMFSs and discuss the discoveries of these studies that provide new insights in the pathophysiology of these conditions.
诱导多能干细胞(iPSC)具有分化为几乎任何类型细胞的可塑性,并且从患者来源的iPSC(iPSC-HSPC)生成造血干祖细胞(HSPC)的可行性在血液学中有许多潜在应用。例如,iPSC-HSPC正被用于白血病发生研究,并且其在各种细胞替代疗法中的应用正在评估中。iPSC-HSPC的使用现在可以为研究与HSPC破坏相关的疾病,如骨髓衰竭综合征(BMFS),提供宝贵资源。最近的研究表明,从获得性再生障碍性贫血和其他BMFS患者中生成iPSC-HSPC不仅可行,而且是理解这些疾病发病机制的有力工具。在本文中,我们重点介绍了iPSC在BMFS疾病建模应用方面的最新进展,并讨论了这些研究的发现,这些发现为这些病症的病理生理学提供了新的见解。